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Aneuploidy screening: Newer 
noninvasive test gains traction
Favorable results from the 2 studies reviewed here have 
prompted ACOG to recommend that cell-free DNA 
screening be discussed with all pregnant patients. 
PRACTICE CHANGER 
Discuss cell-free DNA testing when offering fe-
tal aneuploidy screening to pregnant women.1,2
STRENGTH OF RECOMMENDATION
A: Based on multiple large, multi-center co-
hort studies.
Bianchi DW, Parker RL, Wentworth J, et al; CARE Study Group. DNA 
sequencing versus standard prenatal aneuploidy screening. N Engl J 
Med. 2014;370:799-808.1
Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for 
noninvasive examination of trisomy. N Engl J Med. 2015;372:1589-
1597.2
ILLUSTRATIVE CASE
A 28-year-old gravida 2, para 1001 at 10 weeks 
gestation presents to your clinic for a routine 
first-trimester prenatal visit. Her first child has 
no known chromosomal abnormalities and 
she has no family history of aneuploidy. She 
asks you which tests are available to screen 
her fetus for chromosomal abnormalities.
Pregnant women have traditionally been offered some combination of serum biomarkers and nuchal trans-
lucency to assess the risk of fetal aneuploidy. 
Cell-free DNA testing (cfDNA) is a form of 
noninvasive prenatal testing that uses ma-
ternal serum samples to conduct massively 
parallel sequencing of cell-free fetal DNA 
fragments. It has been offered to pregnant 
women as a screening test to detect fetal 
chromosomal abnormalities since 2011 after 
multiple clinical studies found high sensi-
tivities, specificities, and negative predictive 
values (NPVs) for detecting aneuploidy.3-6 
However until 2015, practice guidelines from 
the American Congress of Obstetricians and 
Gynecologists (ACOG) recommended that 
standard aneuploidy screening or diagnostic 
testing be offered to all pregnant women and 
cfDNA be reserved for women with pregnan-
cies at high risk for aneuploidy (strength of 
recommendation: B).7
CARE (Comparison of Aneuploidy Risk 
Evaluation) and NEXT (Noninvasive Exami-
nation of Trisomy) are 2 large studies that 
compared cfDNA and standard aneuploidy 
screening methods in pregnant women at low 
risk for fetal aneuploidy. Based on new data 
from these and other studies, ACOG and the 
Society for Maternal-Fetal Medicine (SMFM) 
released a new consensus statement in June 
2015 that addressed the use of  cfDNA in the 
general obstetric population. The 2 groups 
still recommend conventional first- and sec-
ond-trimester screening by serum chemical 
biomarkers and nuchal translucency as the 
first-line approach for low-risk women who 
want to pursue aneuploidy screening; how-
ever, they also recommend that the risks and 
benefits of cfDNA should be discussed with 
all patients.8
STUDY SUMMARIES
CARE was a prospective, blinded, multi-
center (21 US sites across 14 states) study that 
compared the aneuploidy detection rates of 
cfDNA to those of standard screening. Stan-
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dard aneuploidy screening included assays 
of first- or second-trimester serum biomark-
ers with or without fetal nuchal translucency 
measurement.
This study enrolled 2042 pregnant pa-
tients ages 18 to 49 (mean: 29.6 years) with 
singleton pregnancies. The population 
was racially and ethnically diverse (65% 
white, 22% black, 11% Hispanic, 7% Asian). 
This study included women with diabetes 
mellitus, thyroid disorders, and other co-
morbidities. cfDNA testing was done on 
1909 maternal blood samples for trisomy 
21 and 1905 for trisomy 18. 
cfDNA and standard aneuploidy screen-
ing results were compared to pregnancy 
outcomes. The presence of aneuploidy was 
determined by physician-documented new-
born physical exam (97%) or karyotype anal-
ysis (3%). In both live and non-live births, the 
incidence of trisomy 21 was 5 of 1909 cases 
(0.3%) and the incidence of trisomy 18 was 
2 of 1905 cases (0.1%). 
The NPV of cfDNA in this study was 
100% (95% confidence interval, 99.8%-100%) 
for both trisomy 21 and trisomy 18. The posi-
tive predictive value (PPV) was higher with 
cfDNA compared to standard screening 
(45.5% vs 4.2% for trisomy 21 and 40% vs 
8.3% for trisomy 18). This means that ap-
proximately 1 in 25 women with a positive 
standard aneuploidy screen actually has an-
euploidy. In contrast, nearly one in 2 women 
with a positive cfDNA result has aneuploidy. 
Similarly, false positive rates with cfD-
NA were significantly lower than those with 
standard screening. For trisomy 21, the cfD-
NA false positive rate was 0.3% compared 
to 3.6% for standard screening (P<.001); for 
trisomy 18, the cfDNA false positive rate was 
0.2% compared to 0.6% for standard screen-
ing (P=.03).
❚ NEXT was a prospective, blinded co-
hort study that compared cfDNA testing 
with standard first-trimester screening (with 
measurements of nuchal translucency and 
serum biochemical analysis) in a routine 
prenatal population at 35 centers in 6 coun-
tries. 
This study enrolled 18,955 women ages 
18 to 48 (mean: 31 years) who underwent 
traditional first-trimester screening and 
cfDNA testing. Eligible patients included 
pregnant women with a singleton pregnan-
cy with a gestational age between 10 and 
14.3 weeks. Prenatal screening results were 
compared to newborn outcomes using a 
documented newborn physical examination 
and, if performed, results of genetic testing. 
For women who had a miscarriage or still-
birth or chose to terminate the pregnancy, 
outcomes were determined by diagnostic 
genetic testing.
The primary outcome was the area un-
der the receiver-operating-characteristic 
(ROC) curve for trisomy 21. Area under 
the ROC curve is a measure of a diagnostic 
test’s accuracy that plots sensitivity against 
1-specificity; <.700 is considered a poor test, 
whereas 1.00 is a perfect test. A secondary 
analysis evaluated cfDNA testing in low-risk 
women (ages <35 years). 
The area under the ROC curve was 
0.999 for cfDNA compared with 0.958 for 
standard screening (P=.001). For diagnosis 
of trisomy 21, cfDNA had a higher PPV than 
standard testing (80.9% vs 3.4%; P<.001) and 
a lower false positive rate (0.06% vs 5.4%; 
P<.001). These findings were consistent in 
the secondary analysis of low-risk women.
Both the CARE and NEXT trials also 
evaluated cfDNA testing vs standard screen-
ing for diagnosis of trisomy 13 and 18 and 
found higher PPVs and lower false positive 
rates for cfDNA compared with traditional 
screening.
WHAT’S NEW
Previously, cfDNA was recommended only 
for women with high-risk pregnancies. The 
new data demonstrate that cfDNA has sub-
stantially better PPVs and lower false positive 
rates than standard fetal aneuploidy screen-
ing for the general obstetrical population.
So while conventional screening tests 
remain the most appropriate methods for 
aneuploidy detection in the general obstet-
rical population, according to ACOG and 
SMFM, the 2 groups now recommend that 
all screening options—including cfDNA—be 
discussed with every woman. Any woman 
may choose cfDNA but should be counseled 
about the risks and benefits.8
cfDNA can’t 
detect neural 
tube or ventral 
wall defects, 
so women who 
choose this 
method should 
be offered  
maternal  
serum alpha-
fetoprotein 
or ultrasound 
evaluation.
ANEUPLOIDY SCREENING
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Many insurance 
companies do 
not yet cover 
cfDNA for  
women with 
low-risk  
pregnancies, 
and the test  
may cost  
up to $1,700.
CAVEATS
Both the CARE and NEXT studies had limi-
tations. They compared cfDNA testing with 
first- or second-trimester screening and did 
not evaluate integrated screening meth-
ods (sequential first- and second-trimes-
ter biomarkers plus first-trimester nuchal 
translucency), which have a slightly higher 
sensitivity and specificity than first-trimester 
screening alone.
Multiple companies offer cfDNA, and 
the test is not subject to Food and Drug Ad-
ministration approval. The CARE and NEXT 
studies used tests from companies that pro-
vided funding for these studies and employ 
several of the study authors. 
Although cfDNA has increased speci-
ficity compared to standard screening, 
there have been case reports of false nega-
tive results. Further testing has shown that 
such false negative results could be caused 
by mosaicism in either the fetus and/or 
placenta, vanishing twins, or maternal 
malignancies.8-10 
 In the CARE and NEXT trials, cfDNA 
produced no results in 0.9% and 3% of wom-
en, respectively. Patients for whom cfDNA 
testing yields no results have higher rates of 
aneuploidy, and therefore require further di-
agnostic testing. 
Because the prevalence of aneuploidy 
is lower in the general obstetric population 
than it is among women whose pregnan-
cies are at high risk for aneuploidy, the PPV 
of cfDNA testing is also lower in the general 
obstetric population. This means that there 
are more false positive results for women 
at lower risk for aneuploidy. Therefore, it is 
imperative that women with positive cfDNA 
tests receive follow-up diagnostic testing 
such as chorionic villus sampling or am-
niocentesis before making a decision about 
termination. 
All commercially available cfDNA tests 
have high sensitivity and specificity for triso-
my 21, 18, and 13. Some offer testing for sex 
chromosome abnormalities and microdele-
tions. However, current cfDNA testing meth-
ods are unable to detect up to 17% of other 
clinically significant chromosomal abnor-
malities,11 and cfDNA cannot detect neural 
tube or ventral wall defects. Therefore, ACOG 
and SMFM recommend that women who 
choose cfDNA as their aneuploidy screen-
ing method should also be offered mater-
nal serum alpha-fetoprotein or ultrasound 
evaluation.
CHALLENGES TO IMPLEMENTATION
cfDNA testing is validated only for single-
ton pregnancies. Physicians should obtain 
a baseline fetal ultrasound to confirm the 
number of fetuses, gestational age, and vi-
ability before ordering cfDNA to ensure it is 
the most appropriate screening test. This may 
add to the overall number of early pregnancy 
ultrasounds conducted. 
Counseling patients about aneuploidy 
screening options is time-consuming, and 
requires discussion of the limitations of each 
screening method and caution that a negative 
cfDNA result does not guarantee an unaffect-
ed fetus, nor does a positive result guaran-
tee an affected fetus. However, aneuploidy 
screening is well within the scope of care for 
family physicians who provide prenatal care, 
and referral to genetic specialists is not nec-
essary or recommended. 
Some patients may request cfDNA in or-
der to facilitate earlier identification of fetal 
sex. In such cases, physicians should advise 
patients that cfDNA testing also assesses tri-
somy risk. Patients who do not wish to assess 
their risk for aneuploidy should not receive 
cfDNA testing.
Finally, while cfDNA is routinely recom-
mended for women with pregnancies con-
sidered at high risk for aneuploidy, many 
insurance companies do not cover the cost 
of cfDNA for women with low-risk pregnan-
cies, and the test may cost up to $1,700.12 
The overall cost-effectiveness of cfDNA for 
aneuploidy screening in low-risk women is 
unknown.                 JFP
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